Literature DB >> 3545103

Cold-induced Raynaud's phenomenon ameliorated by intravenous administration of ketanserin: a double-blind cross-over study.

H Baart de la Faille, H van Weelden, J D Banga, R G van Kesteren.   

Abstract

Fifteen patients suffering from Raynaud's phenomenon (RP) were examined. They were placed in a "climate chamber" (a small room in which the temperature and humidity could be varied). The temperature was gradually decreased, while the humidity was kept constant. After 60-90 min, distinct RP was induced and intravenous medication was administered. The whole trial was performed in a double-blind, cross-over fashion. Every patient participated in two experiments performed 2 days apart. Either ketanserin or placebo was given during the first experiment. In the second experiment, the medication (or placebo) which had not been given was administered. The effects of ketanserin were highly significant: the bluish pallor changed into bright erythema and the skin temperature rose significantly. This was interpreted as a spasmolytic effect. Intravenously administered ketanserin has a place in the clinical treatment of acutely deteriorating RP of diverse etiologies.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3545103     DOI: 10.1007/BF00404349

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN: 0340-3696            Impact factor:   3.017


  18 in total

1.  Vasospastic diseases: a review.

Authors:  J D Coffman; W T Davies
Journal:  Prog Cardiovasc Dis       Date:  1975 Sep-Oct       Impact factor: 8.194

2.  Plethysmographic registration of volume changes in a hand vein. Effects of serotonin and of a specific antagonist.

Authors:  A H Jageneau; C Hörig; W Loots; J Symoens
Journal:  Angiology       Date:  1980-12       Impact factor: 3.619

Review 3.  Serotonergic receptor subtypes and vascular reactivity.

Authors:  J M Van Nueten; J E Leysen; F de Clerck; P M Vanhoutte
Journal:  J Cardiovasc Pharmacol       Date:  1984       Impact factor: 3.105

4.  Vascular effects of ketanserin (R 41 468), a novel antagonist of 5-HT2 serotonergic receptors.

Authors:  J M Van Nueten; P A Janssen; J Van Beek; R Xhonneux; T J Verbeuren; P M Vanhoutte
Journal:  J Pharmacol Exp Ther       Date:  1981-07       Impact factor: 4.030

5.  Raynaud's disease, Raynaud's phenomenon, and serotonin.

Authors:  A HALPERN; P H KUHN; H E SHAFTEL; S S SAMUELS; N SHAFTEL; D SELMAN; H G BRICH
Journal:  Angiology       Date:  1960-06       Impact factor: 3.619

6.  Pathogenesis of scleroderma (systemic sclerosis).

Authors:  E C LeRoy
Journal:  J Invest Dermatol       Date:  1982-07       Impact factor: 8.551

7.  The effects of platelet-derived contractile agents on human digital arteries.

Authors:  R F Moulds; V Iwanov; R L Medcalf
Journal:  Clin Sci (Lond)       Date:  1984-04       Impact factor: 6.124

8.  Treatment of Raynaud's phenomenon with ketanserin, a selective antagonist of the serotonin2 (5-HT2) receptor.

Authors:  J R Seibold; A H Jageneau
Journal:  Arthritis Rheum       Date:  1984-02

9.  Treatment of Raynaud's phenomenon with the 5-HT2-receptor antagonist ketanserin.

Authors:  E Stranden; O K Roald; K Krohg
Journal:  Br Med J (Clin Res Ed)       Date:  1982-10-16

10.  Treatment of Raynaud's phenomenon by intravenous infusion of prostacyclin (PGI2).

Authors:  P M Dowd; M F Martin; E D Cooke; S A Bowcock; R Jones; P A Dieppe; J D Kirby
Journal:  Br J Dermatol       Date:  1982-01       Impact factor: 9.302

View more
  3 in total

Review 1.  Ketanserin for Raynaud's phenomenon in progressive systemic sclerosis.

Authors:  J Pope; D Fenlon; A Thompson; B Shea; D Furst; G Wells; A Silman
Journal:  Cochrane Database Syst Rev       Date:  2000

Review 2.  Ketanserin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in hypertension and peripheral vascular disease.

Authors:  R N Brogden; E M Sorkin
Journal:  Drugs       Date:  1990-12       Impact factor: 9.546

3.  Ketanserin treatment and serotonin in patients with primary and secondary Raynaud's phenomenon.

Authors:  B Marasini; M L Biondi; E Bianchi; P Dell'Orto; A Agostoni
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.